Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07902479
Starting soon Not applicable

Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health

NCT07902479 · tracked via the Priya Life Science France tracker
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Phase
Not applicable
Started
2026-10
Last updated
2026-10-28

Condition(s) studied

Multiple SclerosisNeuromyelitis Optica Spectrum DisorderMOG Antibody-Associated DiseaseDemyelinating Autoimmune Diseases, CNS

Investigational drug(s) / intervention(s)

Blood sampling and multi-omic profiling

Blood sampling and multi-omic profiling: One venous blood sample (50 mL) is drawn at a single visit. DNA is used for whole-genome sequencing. Cryopreserved peripheral blood mononuclear cells (PBMCs) are used for DNA methylation profiling and RNA sequencing. Serum is used to measure GFAP and NfL.

Study summary

The goal of this observational study is to learn why some families have several members with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or MOG antibody-associated disease (MOGAD). These diseases happen when the immune system attacks the brain, optic nerves, or spinal cord. The study includes about 500 people from about 100 families: people with one of these diseases and their relatives who do not have it. The main question is: Do rare gene changes (variants) shared by family members explain why these diseases run in families? Researchers will compare the DNA of family members who have the disease with the DNA of relatives who do not. They will also look at how genes are switched on and off in blood cells. Participants will:

* Attend one visit of 2 to 3 hours at one of five French hospitals
* Answer questions about their health, treatments, and family history
* Give a 50 mL blood sample

Eligibility

Sex
ALL
Min age
15 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Affected participants: * Age 15 years and 3 months or older * Multiple sclerosis (2024 McDonald criteria), neuromyelitis optica spectrum disorder with anti-AQP4 antibodies (2015 Wingerchuk criteria), or MOG antibody-associated disease (2023 international MOGAD panel criteria) * Member of a multiplex family: at least two affected members sharing at least 12.5% of their genetic heritage * Affiliated to a social security scheme or equivalent * Written informed consent (for minors: assent of the minor and consent of the holders of parental authority) * Unaffected relatives: * Age 18 years or older * Sharing at least 25% of genetic heritage with one of the two affected family members * No multiple sclerosis, NMOSD, MOGAD, or other known inflammatory disease of the central nervous system * Affiliated to a social security scheme or equivalent * Written informed consent * Transcriptomic sub-cohort (30 to 60 participants, about 10 families): * Patients with no immunomodulatory or immunosuppressive treatment for at least 12 months, and their relatives Exclusion Criteria: * Refusal to participate before the inclusion visit * Inability to understand the study information or to consent * Person under guardianship, curatorship or legal protection * Person deprived of liberty by judicial or administrative decision * Pregnant or breastfeeding woman * No kinship with at least one affected member of the included family * Refusal to be informed of an incidental discovery of a pathogenic genetic variant

Primary outcome measure(s)

  • Rare high-penetrance variants co-segregating with disease within multiplex families. — 36 months from the first inclusion.
    Proportion of rare (minor allele frequency \< 1%), high-penetrance variants found in affected members and absent or significantly less frequent in unaffected relatives of the same family sharing at least 25% of their genetic heritage. Assessed by co-segregation and linkage analysis, family-based association tests and in silico prediction of variant impact.

Trial sites (5)

FacilityCityRegionStatus
Hospice Civil de Lyon - Hospital Pierre Wertheimer Bron France
University Hospital Laennec Nantes France
University Hospital Pasteur 2 Nice France
Assistance Publique Hôpitaux de Paris- La Pitié Salpêtrière Hospital Paris France
University Hospital Pontchaillou Rennes France

More Institut National de la Santé Et de la Recherche Médicale, France trials in France

Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study Recruiting
Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects Recruiting
Multi-level Approach of Brain Activity Using Intracranial Electrodes in Epileptic Patients Recruiting
Study of the Correlation Between Cortical Excitability and Cytoarchitectonics of Prefrontal Cortex in Healthy Adult Participants, Using Transcranial Magnetic Stimulation Coupled to EEG and High-field MRI Recruiting
IDMet (RaDiCo Cohort) (RaDiCo-IDMet) Recruiting

Other trials for the same condition

3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME) Recruiting
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD Active, not recruiting
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis Active, not recruiting
Detection of Spinal Cord Lesions Using the MP2RAGE Sequence in Inflammatory Diseases of the Neuraxis Recruiting
EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07902479 on ClinicalTrials.gov ↗ ← All trials in France